STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
There are few things in this world more squishy than Wonder Bread. Exception: Biogen’s answers to the question of when it will submit aducanumab to the Food and Drug Administration.
On Wednesday, Biogen said a filing for the controversial Alzheimer’s drug would be completed “as soon as possible.” That’s slightly different but no more definitive than the company’s previous guidance for an aducanumab submission in “early 2020.”
Continue to STAT Plus to read the full story…
